Tyler Dylan-Hyde, Chief Legal Officer at CRISPR Therapeutics AG (CRSP), sold 1,852 shares at $16.61 ($31K) on 2017-05-01, disclosed to the SEC on 2017-05-03.
Scheduled sale ($31k) by Chief Legal Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CRSP | SELL | 2018-01-02 | $840K | — | Filing → |
| CRSP | SELL | 2017-12-27 | $308K | — | Filing → |
| CRSP | SELL | 2017-12-19 | $284K | — | Filing → |